Rutgers Cancer Institute of New Jersey, a National Cancer Institute-designated Comprehensive Cancer Center, is offering a clinical trial as a potential treatment for patients diagnosed with the coronavirus (COVID-19). The trial, which is not limited to cancer patients is exploring hydroxychloroquine and azithromycin.
Research from investigators at Rutgers Cancer Institute of New Jersey shows that a cellular process known as autophagy promotes survival in mouse models by suppressing oxidative stress and a tumor suppressor known as p53.
Research from Rutgers Cancer Institute of New Jersey shows administering the immunotherapy drug pembrolizumab together with chemotherapy given at the same time as radiation treatment (chemoradiation) is safe and tolerable as a first-line therapy for patients with stage 3 non-small cell lung cancer (NSCLC).
Along with a healthy lifestyle, regular screening can help with the prevention of cancer. Rutgers Cancer Institute of New Jersey experts share additional information during this Cancer Prevention Month.
January is Cervical Cancer Awareness Month. A Rutgers Cancer Institute of New Jersey expert shares insight on prevention and early detection of this disease.
An expert from the Rutgers Tobacco Dependence Program shares info and resources on how to quit smoking in the new year.
Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.
Rutgers Cancer Institute of New Jersey investigators evaluated all treatment strategies for both standard-risk and good-risk ductal carcinoma in-situ and found the most commonly recommended combination treatment for DCIS represents low-value care, while radiation therapy alone was cost-effective.
Deep DNA sequencing analysis conducted by Rutgers Cancer Institute of New Jersey investigators examining genomic differences within tumors for prediction of disease relapse in certain hematologic malignancies has identified small mutations. These may help further guide treatment decision making for patients.
Investigators at Rutgers Cancer Institute of New Jersey conducted a retrospective review of patients treated with proton therapy following breast-conserving surgery and found acceptable toxicity rates along with good-to-excellent patient-reported cosmetic outcomes.
A Rutgers Cancer Institute of New Jersey investigator and other collaborators examined prenatal screening practices for blood disorders between different types of care providers and found different variations in prenatal guidance.
Rutgers Cancer Institute of New Jersey investigators compared outcomes for allogeneic stem cell transplant patients when post-transplant cyclophosphamide (PCy) was added as part of standard treatment than if standard treatment was given alone. Results showed an increase in the number of patients who were free of disease and off immunosuppression at one-year in the PCy cohort.
Investigators at Rutgers Cancer Institute of New Jersey have determined that an overabundance of a novel gene known as ADNP in an aggressive form of ovarian cancer may serve as a prognostic tool.
In what is believed to be one of the largest studies of a rare disorder known as primary cutaneous gamma delta T-cell lymphoma, Rutgers Cancer Institute investigators and other collaborators examined characteristics, treatment patterns and outcomes and determined accurate diagnosis of the disease requires ongoing analysis.
The GO2 Foundation for Lung Cancer has awarded $250,000 to investigators at Rutgers Cancer Institute of New Jersey and Princeton University toward the identification and development of novel strategies to address treatment resistance in non-small cell lung cancer.
Gene expression profiling and other analyses conducted by Rutgers Cancer Institute of New Jersey researchers and colleagues examining drug resistance to a common antibody therapy for non-Hodgkin lymphoma have identified calcium signaling as a novel and exploitable target in overcoming this treatment obstacle. Results are being presented at the American Society of Hematology Annual Meeting.
Rutgers Cancer Institute of New Jersey social worker Deborah Leif, MSW, LCSW offers some tips for cancer patients and caregivers on how to deal with stress related to the holiday season.
Rutgers Cancer Institute of New Jersey registered dietitian, Kristin Waldron, RD, CSO reminds us about eating healthy this holiday season as part of a cancer preventive lifestyle.
A $150,000 pledge from the Om Foundation will aid investigators at Rutgers Cancer Institute of New Jersey in examining a certain type of medication that impacts gene activity in the treatment of a form of pediatric brain cancer.
More than $2.3 million in Research Scholar Grants from the American Cancer Society have been awarded to three Rutgers Cancer Institute of New Jersey researchers to examine cell metabolism and tumor formation in forms of breast cancer, lung cancer and leukemia.
A Rutgers Cancer Institute of New Jersey researcher has received a $600,000 Translational Award from the V Foundation for Cancer Research to study treatment impact on chronic lymphocytic leukemia.
Experts from the Rutgers Tobacco Dependence Program share more about the causes and risk factors for lung cancer, which include smoking. At focus is prevention, including tobacco cessation.
Reaffirming its commitment to continued growth and excellence, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health welcome Carolyn Hayes, PhD, RN, NEA-BC, as the new Chief Nursing Officer, RWJBarnabas, Oncology Services and Rutgers Cancer Institute.
One of the hallmarks of a National Cancer Institute-designated Comprehensive Cancer Center is the unique oncology expertise exhibited by its clinical team, including board certified oncology pharmacists. A Rutgers Cancer Institute of New Jersey expert shares more on their role in patient care.
M. Michele Blackwood, MD, FACS, chief of breast surgery at Rutgers Cancer Institute of New Jersey and medical director/Northern regional director of breast services at RWJBarnabas Health, clears up some misconceptions about breast cancer.
M. Michele Blackwood, MD, FACS, chief of breast surgery at Rutgers Cancer Institute of New Jersey and medical director/Northern regional director of breast services at RWJBarnabas Health, shares expertise on breast cancer prevention and advances in breast cancer care.
Although cure rates for children with cancer are increasing, cancer treatments can cause permanent deterioration of brain functions leading to impairments in attention, concentration, memory and learning. With the aid of a $3.4 million NIH grant, a Rutgers Cancer Institute of New Jersey investigator and others are exploring an approach that would detect these changes among children with acute lymphoblastic leukemia early during treatment. The goal is to identify a subset of patients who would benefit from a behavioral intervention or treatment clinical trial.
M. Michele Blackwood, MD, FACS, chief of breast surgery at Rutgers Cancer Institute of New Jersey and medical director/Northern regional director of breast services at RWJBarnabas Health, shares expertise on breast cancer risk factors and screening.
As more women live with breast cancer, minimization of significant deformity in the breast after breast preservation is increasingly gaining attention. A Rutgers Cancer Institute of New Jersey surgical oncologist shares some insight.
Ovarian Cancer is expected to impact 22,000 U.S. women this year. Rutgers Cancer Institute of New Jersey Gynecologic Oncologist Dr. Mihae Song shares some facts during this Ovarian Cancer Awareness Month.
September is Thyroid Cancer Awareness Month and Dr. Amanda Laird, Chief of Endocrine Surgery at Rutgers Cancer Institute of New Jersey shares information on types of thyroid cancer, how it is diagnosed and treatment options.
In what is believed to be the largest dataset study to date examining the role of race on survival outcome for pediatric patients with Hodgkin lymphoma, investigators at Rutgers Cancer Institute of New Jersey have found that black patients have significantly worse overall survival at five years than white patients when accounting for all available clinical variables.
From maintaining regular check-ups and keeping up to date with recommended vaccinations to a good diet and exercise, some simple tips can help keep youngsters healthy as they head back to class - and are cancer preventive too.
An estimated 61,780 new cases of leukemia will be diagnosed in the United States this year. Although leukemias are thought to occur in childhood, they can actually present at any age in both children and adults.
A pair of Rutgers Cancer Institute of New Jersey physician-scientists are collaborating on national research projects that received $1.5 million in combined funding from the Oncology Research Information Exchange Network® (ORIEN) New Oncologic Visionary Awards (NOVA) program.
A Rutgers Cancer Institute of New Jersey pediatric hematologist/oncologist has received a $50,000 grant from the Children’s Oncology Group Foundation to help identify new prognostic markers and potential therapeutic targets in pediatric Hodgkin lymphoma.
Several physicians from Rutgers Cancer Institute of New Jersey have been named among ‘New Jersey’s Top Doctors in Cancer Care’ by Castle Connolly Medical Ltd. The listing appeared recently in Jersey’s Best magazine.
More than $2 million in grants recently awarded to a Rutgers Cancer Institute of New Jersey resident researcher will support examination of potential treatment targets for T-cell acute lymphoblastic leukemia (T-ALL).
Anxiety and depression related to childhood cancer survivorship can be challenging for this population. Rutgers Cancer Institute of New Jersey recently educated pediatric cancer survivors about these topics through its Long-term, Information, Treatment Effects and Evaluation Program annual Survivor’s Family Education Night.
Six Flags Great Adventure, RWJBarnabas Health and the Rutgers Cancer Institute of New Jersey have joined forces to fight cancer and celebrate survivorship with the unveiling of Coasters for Cancer - the first roller coaster wrapped in the hand prints of cancer survivors and supporters.
RWJBarnabas Health and Rutgers Cancer Institute of New Jersey, in partnership with New Brunswick Development Corporation announced the development of a new, state-of-the-art, free-standing cancer pavilion in New Brunswick. The initial estimated project cost is $750 million.
Investigators at Rutgers Cancer Institute of New Jersey have developed a computational method that uncovers clinically relevant gene expression patterns in large cohorts of breast cancer patients. This method, which is applicable to the analysis of all cancers, can robustly describe molecular processes that are associated with tumor subtypes and can identify predictive markers of response to treatment or disease recurrence.
Findings from Rutgers Cancer Institute of New Jersey focused on immunotherapy will be featured at the 2019 American Society of Clinical Oncology Annual Meeting being held in Chicago tomorrow through Tuesday.
Investigators at Rutgers Cancer Institute of New Jersey have found that approximately 30 percent of men with localized prostate cancer may have alterations in DNA damage response pathways.
Rutgers Cancer Institute of New Jersey, the state’s only Comprehensive Cancer Center as recognized by the National Cancer Institute (NCI), has been awarded a $15.1 million grant (P30CA072720) as part of its successful 2019 redesignation.
ScreenNJ, a collaborative program led by Rutgers Cancer Institute and funded in part by the New Jersey Department of Health, aims to increase prevention efforts for prevalent cancers thanks to recommendations resulting from a statewide gathering of health care and community leaders.
A cancer diagnosis can have an emotional as well as physical impact on patients, including coping with an uncertain prognosis, making treatment decisions, and learning how to manage treatment effects. A medical library at New Jersey's only NCI-designated Comprehensive Cancer Center is a vital patient resource.
Fast growing brain tumors known as glioblastoma multiforme often present treatment challenges due to their diverse tumor cell types and their ability to spread into healthy brain tissue. A Rutgers Cancer Institute of New Jersey researcher examines the impact of a novel small molecule inhibitor in the treatment of glioblastoma multiforme, using a patient’s own tumors cells with patient derived organoids.
In the search for more effective therapies for breast cancer, researchers from Rutgers Cancer Institute of New Jersey and Rutgers University are targeting opioid receptors to potentially reduce the development and spread of certain breast cancer subtypes.
Phase 1b and phase 2 clinical trials examining pembrolizumab for advanced small cell lung cancer who received two or more lines of prior treatment show anti-tumor activity with durable responses and manageable toxicity. Rutgers Cancer Institute of New Jersey's Dr. Janice Mehnert, an investigator on the work, shares more.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right